2023
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosis
2019
The use of cell free DNA in the diagnosis of HCC
Banini BA, Sanyal AJ. The use of cell free DNA in the diagnosis of HCC. Hepatoma Research 2019, 2019: 34. PMID: 31673629, PMCID: PMC6822275, DOI: 10.20517/2394-5079.2019.30.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDiagnosis of HCCHepatocellular carcinomaNon-invasive biomarkersCommon malignant tumorPotential clinical utilityCell-free nucleic acidsTypes of cancerCell-free DNALiquid biopsy analysisAnalysis of bloodLiver biopsyPeripheral bloodTumor recurrenceMalignant tumorsProstate cancerEarly diagnosisClinical utilityBiopsy analysisAdvanced stageHigh mortalityTreatment monitoringLiquid biopsyDiagnosisBody fluidsBiopsy